Cargando…
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
Multiple system atrophy is a rapidly progressive and fatal neurodegenerative disorder. While numerous preclinical studies suggested efficacy of potentially disease modifying agents, none of those were proven to be effective in large-scale clinical trials. Three major strategies are currently pursued...
Autores principales: | Sidoroff, Victoria, Bower, Pam, Stefanova, Nadia, Fanciulli, Alessandra, Stankovic, Iva, Poewe, Werner, Seppi, Klaus, Wenning, Gregor K., Krismer, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398078/ https://www.ncbi.nlm.nih.gov/pubmed/35491799 http://dx.doi.org/10.3233/JPD-223183 |
Ejemplares similares
-
A Review on the Clinical Diagnosis of Multiple System Atrophy
por: Stankovic, Iva, et al.
Publicado: (2022) -
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
por: Krismer, Florian, et al.
Publicado: (2014) -
Intact Olfaction in a Mouse Model of Multiple System Atrophy
por: Krismer, Florian, et al.
Publicado: (2013) -
Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy
por: Sturm, Edith, et al.
Publicado: (2016) -
Towards translational therapies for multiple system atrophy
por: Kuzdas-Wood, Daniela, et al.
Publicado: (2014)